‌

US Patent 11851491 Compositions and methods for TCR reprogramming using fusion proteins

Patent 11851491 was granted and assigned to Tcr2 Therapeutics Inc. on December, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

Tcr2 Therapeutics Inc.

0

Current Assignee

Tcr2 Therapeutics Inc.

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Robert Hofmeister0

Patrick Baeuerle0

Date of Patent

December 26, 2023

0

Patent Application Number

164624920

Date Filed

November 22, 2017

0

Patent Citations

US Patent 7067318 Methods for transfecting T cells

0

US Patent 7081518 Anti-mesothelin antibodies having high binding affinity

0

US Patent 7144575 Methods for selectively stimulating proliferation of T cells

0

US Patent 7172869 Methods for transfecting T cells

0

US Patent 7175843 Methods for selectively stimulating proliferation of T cells

0

US Patent 7232566 Methods for treating HIV infected subjects

0

US Patent 7371849 Methods of constructing camel antibody libraries

0

US Patent 7572631 Activation and expansion of T cells

0

...

Patent Primary Examiner

Maria G Leavitt

0

Patent abstract

Provided herein are T-cell receptor (TCR) fusion proteins (TFPs) having specificity for one or more tumor cell associated antigens, T cells engineered to express one or more TFP, and methods of use thereof for the treatment of diseases, including cancer.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11851491 Compositions and methods for TCR reprogramming using fusion proteins

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.